Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Non-Current Assets (2020 - 2025)

Pulse Biosciences has reported Non-Current Assets over the past 6 years, most recently at $11.6 million for Q3 2025.

  • Quarterly results put Non-Current Assets at $11.6 million for Q3 2025, down 8.11% from a year ago — trailing twelve months through Sep 2025 was $49.2 million (down 7.13% YoY), and the annual figure for FY2024 was $13.0 million, down 5.89%.
  • Non-Current Assets for Q3 2025 was $11.6 million at Pulse Biosciences, down from $12.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PLSE hit a ceiling of $18.6 million in Q1 2021 and a floor of $11.6 million in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $14.3 million (2023), compared with a mean of $14.8 million.
  • Peak annual rise in Non-Current Assets hit 20.58% in 2021, while the deepest fall reached 27.05% in 2021.
  • Pulse Biosciences' Non-Current Assets stood at $13.8 million in 2021, then grew by 13.77% to $15.7 million in 2022, then dropped by 12.1% to $13.8 million in 2023, then dropped by 5.89% to $13.0 million in 2024, then dropped by 10.78% to $11.6 million in 2025.
  • The last three reported values for Non-Current Assets were $11.6 million (Q3 2025), $12.1 million (Q2 2025), and $12.5 million (Q1 2025) per Business Quant data.